ASCO 2023 | CTC HOXB13 RNA in mCRPC: abiraterone/enzalutamide impact

Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, shares an overview of a retrospective analysis of the PROPHECY (NCT02269982) trial on the impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. HOXB13 expression in circulating tumor cells (CTCs) was categorized into three groups: undetectable CTCs, CTC+ HOXB13-negative, and CTC+ HOXB13-positive. The association between HOXB13 expression and overall survival (OS) and radiographic progression-free survival (rPFS) was explored. Results showed that higher CTC HOXB13 expression was associated with AR-dependent biomarkers in CTCs and was adversely prognostic in the context of potent AR inhibition. The study suggests that this assay could be useful in selecting patients for AR or future HOXB13 targeted therapies in mCRPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.